Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

AdvaMed Lobbying Costs 40% Less in 3Q of 2010

By R&D Editors | January 4, 2011

WASHINGTON (AP) – The medical device industry’s chief advocacy group spent over $358,000 lobbying the federal government in the third quarter of 2010, according to a recent disclosure form.

The group’s lobbying budget was down more than 40 percent from the prior-year period, when it spent over $610,000 to lobby during the negotiations over the Obama health care overhaul.

In the last quarter, AdvaMed, or the Advanced Medical Technology Association, lobbied on efforts in Congress to make it easier for patients to sue medical device companies via personal injury lawsuits.

Medical device companies are largely shielded from patient lawsuits at the state level by a Supreme Court decision that gave federal regulators the final say in declaring a device safe or unsafe. Democrats, backed by trial lawyers and patient groups, want to overturn that decision, which they say misinterprets the law.

AdvaMed has argued that overriding the decision would allow state courts to second-guess medical experts and create a “patchwork of inconsistent and confusing guidance.”

The group, which represents manufacturers of pacemakers and other medical implants, also lobbied both Congress and the Food and Drug Administration on the system for approving certain medical devices. For over 30 years the FDA has granted speedy approval to devices that are similar to products already on the market. This so-called 510(k) process is cheaper and faster than the review process for first-of-a-kind devices, which must go through rigorous medical testing.

Some lawmakers and consumer advocates complain that the 510(k) system has been abused, allowing high-risk devices onto the market without proper review. AdvaMed officials have voiced concern that a safety backlash could make it harder to get new devices on the market in a cost-efficient manner.

AdvaMed, represents Medtronic Inc., Boston Scientific Corp., Abbott Laboratories and most other major device manufacturers. The group filed its quarterly lobbying report on Oct. 20.

Date: January 4, 2011
Source: Associated Press

Related Articles Read More >

This pocket-sized “laboratory” can detect food allergens in minutes
Engineered enzymes turn industrial pollutant Into pharmaceutical building block
Los Alamos’ R&D 100-winning EpiEarth platform helps predict the global outbreaks early
Who’s building in pharma, and who would be spared from 100% tariffs, if enacted
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2025 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

R&D 100 Awards
Research & Development World
  • Subscribe to R&D World Magazine
  • Sign up for R&D World’s newsletter
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE